Thursday Three - VC, PE and DC
IRA Hits Infusion Therapy Providers; Warren Pings FTC on Oncology Consolidation; Coming Soon - Navigator Series with Banjo Health Founder
Each week Jones Point highlights three impactful developments at the intersection of health care, policy and markets. If any of these are actionable for you, if you have any other DC-driven questions or general feedback, feel free to drop us a line at tommy@jonespointdc.com.
VC - Coming Soon - New Navigator Series Episode with Banjo Health - Focused on Improving Prior Auth Process. Next week we are thrilled to release the next episode in our Navigator Series Podcast - where we feature healthcare companies and thought leaders at the crossroads of policy and innovation. Our episode is with Saar Manha - Founder and CEO of Banjo Health - a DMV-based start-up building an innovative pharmacy and medical prior authorization automation platform. Subscribe at the links below.
PE - Warren Turns Focus on Distributor-Oncology Practice Consolidation - Election Will Determine Impact. Earlier this week, Senator Elizabeth Warren (D-MA) urged FTC Chair Lina Khan to take a closer look at McKesson’s proposed acquisition of Core Ventures and Cardinal Health’s acquisition of Integrated Oncology The past several years has seen an increase in private equity activity in this space so this is worth monitoring from a competitive landscape perspective, as opposed to private equity-specific risk. Ultimately the long-term impact will be determined by next Tuesday’s election. If former President Trump wins, Chair Khan will likely step down - minimizing the influence of Senator Warren on anti-trust matters.
DC - IRA Impact Continues - Downstream Impact on Infusion Therapy Providers. As we work through the first corporate earnings since HHS announced the first round of negotiated drug prices, we continue to see the downstream impacts. Earlier this month, United Health mentioned the impact on its Part D plans and yesterday, infusion therapy provider Option Care discussed how the new negotiated price for Stelara, coupled with upcoming biosimilar introduction is leading the manufacturer to “rapidly reduce the spread in which [they] acquire this therapy relative to the reference price.” The read-through and impacts from IRA drug negation will continue to impact players across the healthcare ecosystem and we constantly helping clients both stay in front of these changes and understand the impacts on their businesses - drop us a line at tommy@jonespointdc.com to learn more.